Lisinopril and hyperkalemia
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril and Hyperkalemia: Risk Factors and Clinical Implications
Hyperkalemia Risk with Lisinopril Use
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to treat hypertension and chronic kidney disease (CKD). However, hyperkalemia—an elevated serum potassium level—is a recognized side effect, especially in certain high-risk populations. Studies show that the incidence of hyperkalemia is higher in patients treated with lisinopril compared to some other antihypertensive agents, such as thiazide diuretics or amlodipine, with one large trial reporting a 3.6% incidence in the lisinopril group versus 1.2% in the chlorthalidone group and 1.9% in the amlodipine group .
High-Risk Populations: Chronic Kidney Disease and Diabetes
Patients with CKD are particularly susceptible to hyperkalemia when starting lisinopril. The risk increases with declining kidney function, as the kidneys are less able to excrete potassium. Predictive risk scores have been developed to help clinicians estimate the likelihood of hyperkalemia in CKD patients starting lisinopril, emphasizing the importance of individualized risk assessment . Case reports also highlight that even after discontinuing lisinopril, patients with CKD can experience severe and rapid increases in potassium, especially during periods of physiological stress such as surgery .
Combination Therapy and Increased Hyperkalemia Risk
Combining lisinopril with other agents that affect the renin-angiotensin system, such as angiotensin II receptor blockers (ARBs) like losartan, further increases the risk of hyperkalemia. In patients with type 2 diabetes and proteinuria, adding lisinopril to losartan nearly doubled the incidence of hyperkalemia compared to losartan alone, leading to early termination of a major clinical trial due to safety concerns Clase2014Fried2009. This combination also increased the risk of acute kidney injury without providing additional benefit in slowing kidney disease progression .
Clinical Consequences of Hyperkalemia
Hyperkalemia can have serious, sometimes life-threatening, consequences. It is associated with an increased risk of cardiovascular events and mortality. In hypertensive patients, those who developed hyperkalemia had a higher risk of combined cardiovascular disease compared to those with normal potassium levels . Severe hyperkalemia can also cause paralysis, bradycardia, and, in extreme cases, necessitate emergency interventions such as hemodialysis Cheung2020Belay2013Wilson2009.
Monitoring and Management Recommendations
Given the potential for severe outcomes, regular monitoring of serum potassium is essential for patients on lisinopril, especially those with CKD, diabetes, or those taking other medications that can increase potassium levels. Dose adjustments based on kidney function and careful consideration of drug combinations are recommended to minimize risk Johnson2010De Jong1990. In cases of overdose or severe hyperkalemia, prompt medical intervention, including possible hemodialysis, may be required .
Conclusion
Lisinopril is effective for managing hypertension and slowing CKD progression, but it carries a risk of hyperkalemia, particularly in patients with impaired kidney function or when used in combination with other renin-angiotensin system inhibitors. Careful patient selection, regular potassium monitoring, and individualized dosing are key strategies to reduce the risk of hyperkalemia and its potentially serious complications Alderman2012Clase2014Johnson2010+4 MORE.
Sources and full results
Most relevant research papers on this topic
CLINICAL SIGNIFICANCE OF INCIDENT HYPOKALEMIA AND HYPERKALEMIA IN TREATED HYPERTENSIVE PATIENTS IN ALLHAT
Hypokalemia and hyperkalemia are common in hypertensive patients, but their impact on mortality is unrelated to the specific effects of thiazide diuretics.
Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan).
Angiotensin II receptor blocker (Losartan) is less likely to cause hyperkalemia than ACEI (Lisinopril) in high-risk patients with a history of high normal serum potassium levels.
Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria
Adding lisinopril to losartan increased the risk of hyperkalemia and acute kidney injury in veterans with type 2 diabetes and proteinuria.
Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril
A prognostic risk score can predict the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril, potentially improving management.
Severe Hyperkalemia During a Robot-Assisted Total Radical Prostatectomy in a Patient with Stage 3a Chronic Kidney Disease: A Case Report.
A patient with stage 3a chronic kidney disease experienced severe hyperkalemia during a robot-assisted prostatectomy, despite prior drug discontinuation.
Apparent lisinopril overdose requiring hemodialysis.
An apparent lisinopril overdose can cause multiorgan dysfunction, but treatment with hemodialysis and supportive care can resolve these abnormalities.
DOI